In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide

Thrombosis Research

Volumn 121, Issue 4, 2008, Pages 493-497

  Petropoulou, Anna D ^a   Gerotziafas, Grigoris T ^b   Samama, Meyer M ^a   Hatmi, Mohamed ^c   Rendu, Francine ^d   Elalamy, Ismail ^b  

^a HÔTEL DIEU   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSTITUT PASTEUR   (France)

^d HÔPITAL BROUSSAIS   (France)

Author keywords

Multiple myeloma; Soluble thrombomodulin; Thalidomide; Thrombin Generation assay

Indexed keywords

DEXAMETHASONE; FIBRINOGEN; THALIDOMIDE; THROMBIN; THROMBOMODULIN;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ENDOTHELIUM INJURY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCOAGULABILITY; IN VITRO STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MONOTHERAPY; MULTIPLE MYELOMA; PRIORITY JOURNAL; STATISTICAL ANALYSIS; THROMBOSIS;

EID: 38649120510     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.05.016     Document Type: Article

References (33)

1. Rajkumar S.V., Leong T., Roche P.C., Fonesca R., Dispenzieri A., Lacy M.Q., et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6 (2000) 3111-3116
2. Vacca A., Ribatti D., Roncali L., Ranieri G., Serio G., Silvestris F., et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87 (1994) 503-508
3. Munshi N.C., and Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 28 (2001) 565-569
4. Rajkumar S.V., Mesa R.A., Fonseca R., Schroeder G., Plevak M.F., Dispenzieri A., et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 8 (2002) 2210-2216
5. Barlogie B., Desikan R., Eddlemon P., Spencer T., Zeldis J., Munshi N., et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98 (2001) 492-494
6. Dimopoulos M.A., Zervas K., Kouvatseas G., Galani E., Grigoraki V., Kiamouris C., et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12 (2001) 991-995
7. Rajkumar S.V., Hayman S., Gertz M.A., Dispenzieri A., Lacy M.Q., Greipp M.R., et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20 (2002) 4319-4323
8. Weber D., Rankin K., Gavino M., Delasalle K., and Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21 (2003) 16-19
9. Zangari M., Barlogie B., Anaissie E., Saghafifar F., Eddlemon P., Jacobson J., et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126 (2004) 715-721
10. Minnema M.C., Fijnheer R., Groot P.G., and Lokhorst H.M. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 1 (2003) 445-449
11. Yagci M., Sucak G.T., and Haznedar R. Fibrinolytic activity in multiple myeloma. Am J Hematol 74 (2003) 231-237
12. Barlogie B., Jagannath S., Desikan K.R., Mattox S., Vesole D., Siegel D., et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93 (1999) 55-65
13. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121 (2003) 749-757
14. Hemker H.C., Giesen P.L., Al Dieri R., Reqnault V., de Smed E., Wagenvoord R., et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33 (2003) 4-15
15. Wielders S., Mukherjee M., Michiels J., Rijkers D.T., Cambus J.P., Knebel R.W., et al. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost 77 (1997) 629-636
16. Hemker H.C., Wielders S., Kessels H., and Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 70 (1993) 617-624
17. Barosi G., Grossi A., Comotti B., Musto P., Gamba G., and Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 114 (2001) 78-83
18. Zangari M., Saghafifar F., Anaissie E., Badros A., Desikan R., Fassas A., et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 13 (2002) 187-192
19. Elice F., Fink L., Tricot G., Barlogie B., and Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 134 (2006) 399-405
20. Auwerda J.J., Sonneveld P., de Maat M.P., and Leebeek F.W. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 92 (2007) 279-280
21. Zangari M., Barlogie B., Thertulien R., Jacobson J., Eddlemon P., Fink L., et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clinical Lymphoma 1 (2003) 32-35
22. Hemker H.C., Giesen P.L., Ramjee M., Wagenvoord R., and Beguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 83 (2000) 589-591
23. Mannucci P.M. The measurement of multi-factorial thrombophilia. Thromb Haemost 88 (2002) 1-2
24. Curvers J., Thomassen M.C., Rimmer J., Hamulyak K., van der Meer J., Tans G., et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 88 (2002) 5-11
25. Kyrle P.A., Mannhalter C., Beguin S., Stumpflen A., Hirschl M., Weltermann A., et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 18 (1998) 1287-1291
26. Rotteveel R.C., Roozendaal K.J., Eijsman L., and Hemker H.C. The influence of oral contraceptives on the time-integral of thrombin generation (thrombin potential). Thromb Haemost 70 (1993) 959-962
27. Brummel-Ziedins K.E., Vossen C.Y., Butenas S., Mann K.G., and Rosendaal F.R. Thrombin generation profiles in deep vein thrombosis. J Thromb Haemost 3 (2005) 2497-2505
28. Gerotziafas G.T., Depasse F., Busson J., Leflem L., Elalamy I., and Samama M.M. Towards a standarization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of thrombogram-thrombinoscope assay. Thromb J 3 (2005) 16
29. Esmon C.T. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 2644 (1989) 4743
30. Ishii H., Uchiyama H., and Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 65 (1991) 6118-6125
31. Corso A., Lorenzi A., Terulla V., Airo F., Varettoni M., Mangiacavalli S., et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 83 (2004) 588-591
32. Zappasodi P., Mangiacavalli S., Terulla V., Airo F., Klersy C., Varettoni M., et al. Thrombomodulin levels are not modified during thalidomide treatment. Eur J Haematol 77 (2006) 453-454
33. Hron G., Kollars M., Binder B.R., Eichinger S., and Kyrle P.A. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 296 (2006) 397-402